EUVIMEDEUVIMED entdecken
Crossref

The use of 1E12, a monoclonal anti-platelet factor 4 antibody, to improve the diagnosis of vaccine-induced immune thrombotic thrombocytopenia

Caroline Vayne, Jérôme Rollin, Rumi Clare, Mercy Daka, Merveille Atsouawe, Eve-Anne Guéry, Philippe Cauchie, Charlotte Cordonnier, Pauline Cuisenier, Emmanuel De Maistre, Magali Donnard, Nicolas Drillaud und 12 weitere

Journal of Thrombosis and Haemostasis · 2024

DOI: 10.1016/j.jtha.2024.05.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Caroline Vayne und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haemostasis, Regional University Hospital Centre Tours, Tours, France; Institut National de la Santé et de la Recherche Médicale INSERM…. Hauptthemen laut MEDLINE: Platelet Factor 4, Heparin, Antibodies, Monoclonal, COVID-19 Vaccines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Region Centre-Val de Loire, Canadian Institutes of Health Research, Public Health Agency of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a complication of adenoviral-based vaccine against SARS-CoV-2 due to prothrombotic immunoglobulin (Ig) G antibodies to platelet factor 4 (PF4) and may be difficult to distinguish from heparin-induced thrombocytopenia (HIT) in patients treated with heparin. OBJECTIVES: We assessed the usefulness of competitive anti-PF4 enzyme immunoassays (EIAs) in this context. METHODS: The ability of F(ab')2 fragments of 1E12, 1C12, and 2E1, 3 monoclonal anti-PF4 antibodies, to inhibit the binding of human VITT or HIT antibodies to PF4 was evaluated using EIAs. Alanine-scanning mutagenesis was performed to define the amino acids involved in the interactions between the monoclonal antibodies and PF4. RESULTS: A strong inhibition of VITT IgG binding to PF4 was measured with 1E12 (median inhibition, 93%; n = 8), whereas it had no effect on the binding of HIT antibodies (median, 6%; n = 8). In contrast, 1C12 and 2E1 inhibited VITT (median, 74% and 76%, respectively) and HIT antibodies (median, 68% and 53%, respectively) binding to PF4. When a competitive anti-PF4 EIA was performed with 1E12 for 19 additional VITT samples, it strongly inhibited IgG binding to PF4, except for 1 patient, who had actually developed HIT according to the clinical history. Epitope mapping showed that 1E12 interacts with 5 key amino acids on PF4, of which 4 are also required for the binding of human VITT antibodies, thus explaining the competitive inhibition. CONCLUSION: A simple competitive anti-PF4 EIA with 1E12 could help confirm VITT diagnosis and distinguish it from HIT in patients when both diagnoses are possible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Factor 4HeparinAntibodies, MonoclonalCOVID-19 VaccinesHumansImmunoglobulin GPredictive Value of TestsAnticoagulantsCOVID-19Immunoglobulin Fab FragmentsProtein BindingPurpura, Thrombocytopenic, IdiopathicSARS-CoV-2Binding, CompetitivePurpura, Thrombotic Thrombocytopenic

Stichwörter der Autor:innen

immunoassayplatelet factor 4thrombocytopeniathrombosisvaccines

Substanzen

Platelet Factor 4PF4 protein, humanHeparinAntibodies, MonoclonalCOVID-19 VaccinesImmunoglobulin GAnticoagulantsImmunoglobulin Fab Fragments

Autor:innen und Institutionen

  • Department of Haemostasis, Regional University Hospital Centre Tours, Tours, France; Institut National de la Santé et de la Recherche Médicale INSERM U1327 ISCHEMIA, Membrane Signalling and Inflammation in Reperfusion I…
  • Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Michael G. DeGroote Centre for Transfusion Research, Hamilton, Ontario, Canada.
  • Institut National de la Santé et de la Recherche Médicale INSERM U1327 ISCHEMIA, Membrane Signalling and Inflammation in Reperfusion Injuries, Université de Tours, Tours, France.
  • Department of Haemostasis, Regional University Hospital Centre Tours, Tours, France.
  • Service de Biologie Clinique, Centre Hospitalier Universitaire de Charleroi, Charleroi, Belgium.
  • Inserm, Centre Hospitalier Universitaire Lille, U1172-Lille Neurosciences and Cognition, University of Lille, Lille, France.

Förderung

  • Region Centre-Val de Loire
  • Canadian Institutes of Health Research
  • Public Health Agency of Canada

Zitieren

APA

Vayne, C., Rollin, J., Clare, R., Daka, M., Atsouawe, M., Guéry, E. A., Cauchie, P., Cordonnier, C., Cuisenier, P., De Maistre, E., Donnard, M., Drillaud, N., Faille, D., Galinat, H., Gouin-Thibault, I., Lemoine, S., Mourey, G., Mullier, F., Siguret, V., …, & Pouplard, C. (2024). The use of 1E12, a monoclonal anti-platelet factor 4 antibody, to improve the diagnosis of vaccine-induced immune thrombotic thrombocytopenia. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.05.005

Vancouver

Vayne C, Rollin J, Clare R, Daka M, Atsouawe M, Guéry EA, et al. The use of 1E12, a monoclonal anti-platelet factor 4 antibody, to improve the diagnosis of vaccine-induced immune thrombotic thrombocytopenia. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.05.005

BibTeX
@article{Vayne2024,
  author = {Vayne, Caroline and Rollin, Jérôme and Clare, Rumi and Daka, Mercy and Atsouawe, Merveille and Guéry, Eve-Anne and Cauchie, Philippe and Cordonnier, Charlotte and Cuisenier, Pauline and De Maistre, Emmanuel and Donnard, Magali and Drillaud, Nicolas and Faille, Dorothée and Galinat, Hubert and Gouin-Thibault, Isabelle and Lemoine, Sandrine and Mourey, Guillaume and Mullier, François and Siguret, Virginie and Susen, Sophie and Godon, Alban and Nazy, Ishac and Gruel, Yves and Pouplard, Claire},
  title = {The use of 1E12, a monoclonal anti-platelet factor 4 antibody, to improve the diagnosis of vaccine-induced immune thrombotic thrombocytopenia},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  doi = {10.1016/j.jtha.2024.05.005}
}
Kostenlos starten →